Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Roshani Patel; Max Gordon; Amrit Bhaskarla; Michael Emanuel; Dana Delgado Colon; Constance Yuan; Liza Lindenberg; Mena Esther; Baris Turkbey; Patel Nisha; Irina Maric; Hao-Wei Wang; Raul Braylan; Calvo Kathy; Mark Roschewski; Ryan Young; Dickran Kazandjian; Elizabeth Hill

doi:10.1016/S2152-2650(25)03804-2

Back

Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Conference poster

Peer reviewed

Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma

Roshani Patel, Max Gordon, Amrit Bhaskarla, Michael Emanuel, Dana Delgado Colon, Constance Yuan, Liza Lindenberg, Mena Esther, Baris Turkbey, Patel Nisha, …

Clinical lymphoma, myeloma and leukemia, Vol.25, p.S240

2025-09

DOI: https://doi.org/10.1016/S2152-2650(25)03804-2

Metrics

1 Record Views

Details

Title: Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Creators: Roshani Patel
Max Gordon
Amrit Bhaskarla
Michael Emanuel
Dana Delgado Colon
Constance Yuan
Liza Lindenberg
Mena Esther
Baris Turkbey
Patel Nisha
Irina Maric
Hao-Wei Wang
Raul Braylan
Calvo Kathy
Mark Roschewski
Ryan Young
Dickran Kazandjian
Elizabeth Hill
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.25, p.S240
Academic Unit: Miller School of Medicine; UMMG Department of Medicine - Myeloma
Language: English
Resource Type: Conference poster
Record Identifier: 991032798691702976